Jagsonpal Pharmaceuticals (JAGSNPHARM) Q3 24/25 earnings summary

Executive summary

• Q3FY25 revenue reached ₹740 million, up 57% year-over-year, with operating EBITDA (pre-ESOP) up 183% to ₹171 million.

• 9MFY25 revenue grew 27% to ₹2,102 million, and operating EBITDA rose 53% to ₹482 million, with a 390 bps margin expansion.

• Unaudited financial results for the quarter and nine months ended 31 December 2024 were reviewed and approved by the Board and Audit Committee on 22 January 2025.

• Statutory auditors conducted a limited review and found no material misstatements.

• Integration of the Yash Pharma acquisition and the sale of the Faridabad facility contributed to performance and strengthened the balance sheet.

Financial highlights

• Q3FY25 gross margin improved to 64.2% from 58.6% in Q3FY24; EBITDA margin rose to 23.1% from 12.8%.

• Q3FY25 PAT (excluding exceptional items) was ₹115 million, up from ₹40 million YoY.

• Net profit for the quarter was ₹319.90 million, up from ₹39.63 million YoY, including an exceptional profit of ₹233.59 million from the Faridabad factory sale.

• Free cash flow for 9MFY25 was ₹349 million; cash and equivalents stood at ₹1,321 million as of Dec 31, 2024.

• Basic and diluted EPS for the quarter were ₹4.74.

Outlook and guidance

• FY25 revenue growth expected at 30%+; beyond FY25, 12–14% annual growth targeted.

• Operating margins (pre-ESOP) expected at ~22% for FY25, with 100–150 bps improvement beyond FY25.

• Focus remains on organic growth, new product launches (4–6 annually), and strategic inorganic initiatives.

• Earnings per share for all periods have been restated to reflect the recent share split.